{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:29Z","timestamp":1759403429991,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.vaccine.2020.06.043","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:35:06Z","timestamp":1594719306000},"page":"5814-5821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine"],"prefix":"10.1016","volume":"38","author":[{"given":"Marcel E.","family":"Curlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Edlefsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-733X","authenticated-orcid":false,"given":"Kenneth H.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Maenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Keefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C. De","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.06.043_b0005","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.043_b0010","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.043_b0015","doi-asserted-by":"crossref","first-page":"15547","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.06.043_b0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.06.043_b0025","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1128\/JVI.00171-06","article-title":"Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239","volume":"80","author":"Wilson","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.06.043_b0030","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.043_b0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.043_b0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.06.043_b0045","doi-asserted-by":"crossref","first-page":"19940","DOI":"10.1073\/pnas.0907898106","author":"Benlahrech","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.vaccine.2020.06.043_b0050","doi-asserted-by":"crossref","first-page":"13439","DOI":"10.1073\/pnas.1400446111","article-title":"Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals","volume":"111","author":"Hu","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2020.06.043_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006888","article-title":"Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection","volume":"14","author":"Auclair","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.06.043_b0060","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-gamma secretion with increased HIV-1 infection risk: a cohort-based modeling study","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.043_b0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nm.1989","article-title":"Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells","volume":"15","author":"Hutnick","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.06.043_b0070","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1084\/jem.20081786","article-title":"Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells","volume":"205","author":"Perreau","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.06.043_b0075","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2020.06.043_b0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Aste-Amezaga","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2020.06.043_b0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jim.2007.02.003","article-title":"Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials","volume":"322","author":"Bull","year":"2007","journal-title":"J Immunol Methods."},{"key":"10.1016\/j.vaccine.2020.06.043_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-1759(03)00255-2","article-title":"Optimization of methods to assess human mucosal T-cell responses to HIV infection","volume":"279","author":"Shacklett","year":"2003","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.06.043_b0095","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.06.043_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137666","article-title":"Continued follow-up of phambili phase 2b randomized HIV-1 vaccine trial participants supports increased HIV-1 acquisition among vaccinated men","volume":"10","author":"Moodie","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.043_b0105","doi-asserted-by":"crossref","first-page":"13026","DOI":"10.1073\/pnas.0404739101","article-title":"Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein","volume":"101","author":"Staprans","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2020.06.043_b0110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","article-title":"Vaccine-induced enhancement of viral infections","volume":"27","author":"Huisman","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.06.043_b0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2020.06.043_b0120","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"New Engl J Medi"},{"key":"10.1016\/j.vaccine.2020.06.043_b0125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1089\/aid.1993.9.1175","article-title":"Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials","volume":"9","author":"Mascola","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2020.06.043_b0130","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1570162X113116660062","article-title":"Antibody-dependent enhancement and the risk of HIV infection","volume":"11","author":"Gorlani","year":"2013","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.vaccine.2020.06.043_b0135","article-title":"Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination","volume":"7","author":"Cheng","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.06.043_b0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nm.1991","article-title":"Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans","volume":"15","author":"O'Brien","year":"2009","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030829X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2030829X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:45:28Z","timestamp":1759401928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2030829X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":28,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0264410X2030829X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}